Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

NCT06612203 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: Debio 0123 and Sacituzumab govitecan

Sponsor

MedSIR

Collaborators

[object Object]
[object Object]